| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Shruti H Mehta | Q85470954 |
| David L Thomas | Q89653947 | ||
| Mark Sulkowski | Q89653950 | ||
| Thierry Poynard | Q43252014 | ||
| P2093 | author name string | C Graham | |
| R T Schooley | |||
| N H Afdhal | |||
| S Zeuzem | |||
| H Razavi | |||
| D R Church | |||
| I M Jacobson | |||
| J W Ward | |||
| A H Talal | |||
| A Muir | |||
| A H Litwin | |||
| L Castera | |||
| L Dee | |||
| New Paradigm of HCV Therapy Meeting Participants | |||
| P2860 | cites work | Referral for chronic hepatitis C treatment from a drug dependency treatment setting. | Q50574950 |
| Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). | Q51751471 | ||
| Institute of Medicine recommendations for the prevention and control of hepatitis B and C. | Q51781125 | ||
| Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. | Q52286667 | ||
| Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. | Q53118691 | ||
| American Gastroenterological Association medical position statement on the management of hepatitis C | Q82213457 | ||
| Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement | Q22305313 | ||
| Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma | Q22305316 | ||
| Outcomes of treatment for hepatitis C virus infection by primary care providers | Q24601722 | ||
| An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases | Q24632766 | ||
| Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis | Q26822903 | ||
| Hepatitis C virus infection in san francisco’s HIV-infected urban poor | Q27473306 | ||
| Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients | Q28274666 | ||
| Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention | Q28286743 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options | Q29620126 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Non-invasive markers for hepatic fibrosis | Q30474093 | ||
| A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment | Q30540697 | ||
| Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment | Q31122023 | ||
| Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers | Q33389189 | ||
| Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy | Q33767530 | ||
| Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. | Q33834953 | ||
| The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings | Q33834958 | ||
| Successful integration of hepatitis C evaluation and treatment services with methadone maintenance | Q33858467 | ||
| Mental and physical symptoms associated with lower social support for patients with hepatitis C. | Q33867829 | ||
| Preliminary study of two antiviral agents for hepatitis C genotype 1. | Q34030288 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 | ||
| Economic burden of hepatitis C-associated diseases in the United States. | Q34253963 | ||
| Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement | Q34293132 | ||
| Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. | Q34294185 | ||
| Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. | Q34320498 | ||
| Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. | Q34344995 | ||
| Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? | Q40234175 | ||
| Projecting future complications of chronic hepatitis C in the United States | Q40594872 | ||
| Managing chronic hepatitis C acquired through intravenous drug use. | Q40718332 | ||
| Faldaprevir and deleobuvir for HCV genotype 1 infection. | Q42276796 | ||
| Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study | Q42280287 | ||
| Recommendations for the management of hepatitis C virus infection among people who inject drugs. | Q42280296 | ||
| Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre | Q42510746 | ||
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial | Q42943536 | ||
| Exploratory study of oral combination antiviral therapy for hepatitis C. | Q42987725 | ||
| The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States | Q42988978 | ||
| Testing for HCV infection: an update of guidance for clinicians and laboratorians | Q42991914 | ||
| Hepatitis C in the United States | Q42992102 | ||
| Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial | Q42992205 | ||
| Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. | Q42993200 | ||
| High rates of uninsured among HCV-positive individuals | Q42994988 | ||
| Management of hepatitis C patients by primary care physicians in the USA: results of a national survey | Q43034294 | ||
| Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites | Q43040568 | ||
| Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia | Q43584066 | ||
| Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. | Q43875619 | ||
| Surprisingly small effect of antiviral treatment in patients with hepatitis C. | Q43889137 | ||
| Expanded hepatitis C virus screening recommendations promote opportunities for care and cure | Q44151926 | ||
| Transient elastography for predicting clinical outcomes in patients with chronic liver disease | Q44301837 | ||
| Cost-effectiveness of screening for chronic hepatitis C infection in the United States. | Q44409469 | ||
| Biopsy no more; changing the screening and diagnostic algorithm for hepatitis C. | Q44871885 | ||
| The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. | Q44979610 | ||
| HCV screening practices and prevalence in an MCO, 2000-2007. | Q45112392 | ||
| The impact of injecting drug use status on hepatitis C-related referral and treatment | Q45193444 | ||
| Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. | Q45366817 | ||
| Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects | Q45413404 | ||
| Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations | Q46078112 | ||
| Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection | Q34386833 | ||
| Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 | ||
| Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. | Q34542083 | ||
| Performance of transient elastography for the staging of liver fibrosis: a meta-analysis | Q34590187 | ||
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection | Q34607097 | ||
| Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat | Q34628400 | ||
| Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors | Q34719654 | ||
| Barriers to the treatment of hepatitis C. Patient, provider, and system factors | Q34723678 | ||
| Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review | Q34754575 | ||
| The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre | Q36011960 | ||
| New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis | Q36652084 | ||
| A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease? | Q36779473 | ||
| Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance | Q37002923 | ||
| Outcomes of a Hepatitis C screening program at a large urban VA medical center | Q37039558 | ||
| Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy | Q37042425 | ||
| Chronic hepatitis C virus (HCV) disease burden and cost in the United States | Q37148328 | ||
| Limited uptake of hepatitis C treatment among injection drug users | Q37238205 | ||
| Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV | Q37252421 | ||
| Antiviral therapy for hepatitis C: why are so few patients being treated? | Q37749115 | ||
| Manifestations of chronic hepatitis C virus infection beyond the liver | Q37792523 | ||
| Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis | Q37841383 | ||
| All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective | Q37922772 | ||
| Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients | Q37976169 | ||
| Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic | Q38042963 | ||
| Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. | Q38062975 | ||
| Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. | Q38123945 | ||
| Hepatitis C treatment eligibility in an urban population with and without HIV coinfection | Q39685034 | ||
| Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic | Q39775580 | ||
| Integrating HCV services for drug users: a model to improve engagement and outcomes | Q39813191 | ||
| Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. | Q39874376 | ||
| Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals | Q39910287 | ||
| Public health impact of antiviral therapy for hepatitis C in the United States | Q39939298 | ||
| Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk | Q40021862 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 11 | |
| P921 | main subject | best practice | Q830382 |
| chronic hepatitis C | Q55779873 | ||
| mass screening | Q64733553 | ||
| preventive health services | Q65732032 | ||
| biomedical investigative technique | Q66648976 | ||
| RNA virus infectious disease | Q18967413 | ||
| antiviral agent | Q40207875 | ||
| P304 | page(s) | 745-760 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
| P1476 | title | The new paradigm of hepatitis C therapy: integration of oral therapies into best practices | |
| P478 | volume | 20 |
| Q36595767 | "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment |
| Q47156419 | 'Sussing that doctor out.' Experiences and perspectives of people affected by hepatitis C regarding engagement with private general practitioners in South Australia: a qualitative study |
| Q37018850 | Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States |
| Q35563500 | Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy. |
| Q28070280 | Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections |
| Q36406176 | Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. |
| Q36259445 | Cancers attributable to infections among adults with HIV in the United States |
| Q37543670 | Characterizing Failure to Establish Hepatitis C Care of Baby Boomers Diagnosed in the Emergency Department |
| Q64124224 | Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons |
| Q34735072 | Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs |
| Q38947375 | Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C. |
| Q33858322 | Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target? |
| Q37220279 | Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama |
| Q38991902 | Engagement in the Hepatitis C Care Cascade Among Homeless Veterans, 2015. |
| Q55717379 | Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. |
| Q40091374 | Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial |
| Q40934454 | For patients with rheumatic disease and hepatitis C infection: the end of interferon. |
| Q31012317 | HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape |
| Q36285092 | Health state utilities associated with attributes of treatments for hepatitis C. |
| Q37578288 | Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy |
| Q42220208 | Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). |
| Q38408888 | Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents |
| Q26768274 | Hepatitis C virus: A time for decisions. Who should be treated and when? |
| Q40873258 | High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy |
| Q40966047 | Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers - Philadelphia, Pennsylvania, 2012-2014. |
| Q26771433 | Imaging Based Methods of Liver Fibrosis Assessment in Viral Hepatitis: A Practical Approach |
| Q56654945 | Increasing hepatitis C screening in a large integrated health system: science and policy in concert |
| Q41256468 | Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study |
| Q47973294 | Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients |
| Q40561879 | Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion |
| Q40921653 | Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion |
| Q34028307 | Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. |
| Q41929182 | Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C. |
| Q38696250 | Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. |
| Q35639889 | Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy |
| Q36813466 | Public health clinic-based hepatitis C testing and linkage to care in Baltimore. |
| Q35752660 | Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program |
| Q33797817 | Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. |
| Q38219424 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. |
| Q36849533 | The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic |
| Q41463702 | The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment |
| Q35674832 | The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report |
| Q40649732 | The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand |
| Q35593482 | The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014 |
| Q40219302 | Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. |
| Q26784321 | Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin |
Search more.